ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2022
Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Diversity and function of OXA-48-like β-lactamase variants in environmentalApplied and environmental microbiology · 2026Article
- Epidemiological and Molecular Surveillance of Multiresistant Citrobacter freundii Complex in a Tertiary Care Hospital: A Retrospective Cohort Study.The Journal of infectious diseases · 2026Article
- Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica.The Journal of antimicrobial chemotherapy · 2026Article
- Genetic characterization of tigecycline and carbapenem resistant Acinetobacter baumannii in a tertiary care hospital of Northern India.BMC microbiology · 2026Article
- Molecular Epidemiology of NDM-ProducingMicroorganisms · 2026Article
- Pre-trained ChatGPT for report generation in automated microbial identification and antibiotic susceptibility testing systems.Scientific reports · 2025Article
- Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas.The Journal of antimicrobial chemotherapy · 2025Article
- High-level cefiderocol and ceftazidime/avibactam resistance in KPC-producing Klebsiella pneumoniae associated with mutations in KPC and the sensor histidine kinase EnvZ.The Journal of antimicrobial chemotherapy · 2025Article
- Plasmid genomic epidemiology of carbapenem-hydrolysing class D β-lactamase (CDHL)-producingMicrobial genomics · 2024Article
- Monitoring ESBL-mSphere · 2024Article
- Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador.BMC infectious diseases · 2024Article
- In vivo development of cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii associated with the downregulation of a TonB-dependent siderophore receptor, PiuA.The Journal of antimicrobial chemotherapy · 2024Article
- Modification of the penicillin-binding-protein 3 as a source of resistance to broad-spectrum cephalosporins in Escherichia coli.The Journal of antimicrobial chemotherapy · 2024Article
- Effect of Zinc Oxide and Copper Sulfate on Antibiotic Resistance Plasmid Transfer inMicroorganisms · 2023Article
- Dissemination of ArmA- and OXA-23-co-producing Acinetobacter baumannii Global Clone 2 in Switzerland, 2020-2021.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Antibiotic Resistance in Selected Emerging Bacterial Foodborne Pathogens-An Issue of Concern?Antibiotics (Basel, Switzerland) · 2023Review
- Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Emergence of Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae in Switzerland.Antimicrobial agents and chemotherapy · 2023Article
- Characterization of Third Generation Cephalosporin- and Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OXA-48-type ß-lactamases are the most prevalent carbapenemase-type in Enterobacterales in Switzerland, predominantly found in Escherichia coli and Klebsiella pneumoniae. Bacteria-producing OXA-48-type enzymes are endemic in some parts of the world, including Europe and North Africa, and are a frequent cause of nosocomial infections. Despite the emergence of numerous OXA-48-type variants, the original variant, OXA-48, remains the most prevalent in E. coli. This study describes the epidemiology of OXA-48-producing E. coli isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) between January 2019 and December 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.